US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Aardvark Therapeutics, Inc.

News headline image
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces Leadership Appointments
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD
News headline image
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
From Aardvark Therapeutics, Inc.
Via GlobeNewswire
Tickers AARD